## REMARKS

This Amendment is submitted in response to the Examiner's communication dated February 19, 2002, which indicated that Applicants' previous submission on November 13, 2001, failed to comply with the Rules regarding nucleic acid and amino acid sequence disclosures. Specifically, the sheet attached to the Examiner's Communication required that Applicants submit a substitute sequence listing because it did not appear as if all the sequences in the application were included in the sequence listing. The attachment mentioned in particular the sequence at page 8, line 14 of the application (see section 7 of the Attachment).

Applicants respectfully submit that all the sequences were included in the sequence listing as filed. For instance, the sequence at page 8, line 14 is SEQ ID NO: 18 in the sequence listing submitted November 13, 2001. In order to clarify the sequence identities of the sequences on page 8 of the specification, the specification has been amended above to include reference to the appropriate SEQ ID Nos. No new matter has been added.

This Amendment is believed to be fully responsive to the Examiner's Communication dated February 19, 2002. Therefore, substantive examination appears to be next in line and is respectfully requested.

Except for issue fees payable under 37 C.F.R. § 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R § 1.16 and § 1.17 which may be required, or credit

Attorney Docket No. 056159-5061 Application No. 09/626,242 Page 4

any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. § 1.136(a)(3).

Respectfully submitted,

MORGAN, LEWIS & BOCKIUS LLP

Dated: March 19, 2002

By:

Bonnie Weiss McLeod Reg. No. 43,255

Customer No. 09629 MORGAN, LEWIS & BOCKIUS LLP 1111 Pennsylvania Avenue, N.W. Washington, D.C. 20004 (202) 739-3000

## MARKED-UP VERSION

Deletions appear as Overstrike text surrounded by []
Additions appear as Bold text

Figure 2 shows a plasmid map of phage display vector pHEN.5 containing a heavy chain variable domain (HC-V) gene. The DNA and protein sequences of the insertion regions are indicated (SEQ ID NOS: 14-17, respectively in order of appearance).

RR-6 is an azo dye, available from ICI; BSA is bovine serum albumin; myc is a peptide comprising the sequence Glu-Gln-Lys-Leu-Ile-Ser-Glu-Glu-Asp-Leu-Asn (SEQ ID NO: 18).

Figure 5 shows aligned protein sequences of selected anti-RR6 clones

[selected anti-RR6 clones](SEQ ID NOS: 5-10, respectively in

order of appearance). The CDR regions are boxed.

Figure 8 shows aligned protein sequences of the three selected anti-dicarboxylic clones D1, D2, D3 (SEQ ID NOS: 11-13, respectively in order of appearance). The CDR regions are boxed.